ADOCIA Announces the Release of its Universal Registration Document for the Year 2021

Rhea-AI Summary

Adocia, a clinical-stage biopharmaceutical company, filed its 2021 Universal Reference Document with the AMF on April 21, 2022. This document includes the annual financial report, the Management Report, and the corporate governance report. Adocia specializes in innovative treatments for diabetes and metabolic diseases, holding over 25 patent families, and is recognized for its proprietary technologies like BioChaperone® and AdOral®. For further details, the document can be accessed on Adocia's website and the AMF's site.

Positive

• Filed 2021 Universal Reference Document, enhancing transparency.
• Broad portfolio of innovative therapeutic solutions for diabetes and metabolic diseases.
• Ranked highly in patent filings by the French National Institute of Industrial Property.

Negative

• None.

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the filing of its 2021 Universal Reference Document with the “Autorité des marchés financiers” (AMF - the French financial markets regulator) on April 21, 2020.

An electronic copy of this document is available on the company’s website (www.adocia.com) as well as on the website of the AMF (www.amf-france.org). Hard copies are available upon request at the company’s headquarters located 115, avenue Lacassagne, 69003 Lyon.

The universal reference document includes the 2021 annual financial report, which includes the 2021 Management Report and the corporate governance report.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on three proprietary technology platforms:

1) The BioChaperone^® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral^®, an oral peptide delivery technology; 3) AdoShell^®, an immunoprotective biomaterial for cell transplantation with a first application in pancreatic cells transplantation for patients with "brittle" diabetes.

Adocia holds more than 25 patent families and was ranked 4^th and 7^th in the French National Institute of Industrial Property (INPI) ranking of SMEs on the number of patents filed, in 2019 and 2020 respectively.

Based in Lyon, the company has approximately 115 employees. Adocia is listed on the Euronext^TM Paris market (Euronext: ADOC; ISIN: FR0011184241).

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005667/en/

Adocia

Gérard Soula

CEO

contactinvestisseurs@adocia.com

Tel : +33 4 72 610 610

www.adocia.com

Ulysse Communication

Adocia Press and Investors Relations

Pierre-Louis Germain

plgermain@ulysse-communication.com / + 33 (0)6 64 79 97 51

Margaux Puech Pays d’Alissac

mpuech@ulysse-communication.com / +33 (0)7 86 16 01 09

Bruno Arabian

barabian@ulysse-communication.com / +33 (0)6 87 88 47 26

Source: ADOCIA

FAQ

What is the filing date of Adocia's 2021 Universal Reference Document?

Adocia filed its 2021 Universal Reference Document with the AMF on April 21, 2022.

What does the 2021 Universal Reference Document include?

It includes the 2021 annual financial report, Management Report, and corporate governance report.

Where can I find Adocia's Universal Reference Document?

An electronic copy is available on Adocia's website and the AMF's website.

What technologies does Adocia specialize in?

Adocia specializes in BioChaperone®, AdOral®, and AdoShell® technologies for diabetes and metabolic diseases.

How many patents does Adocia hold?

Adocia holds over 25 patent families.